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Endometrial cancerThe use of molecular target therapy has not been established for endometrial cancer. The present study
investigated the potential therapeutic strategy of targeting CD117-positive cancer cells as a novel molec-
ular target therapy. FACS-sorted CD117+ cells isolated from endometrial cancer cell lines (Ishikawa or
MFE280 cells) exhibited higher proliferative capacity in vitro and colony forming activity on soft agar,
and decreased sensitivity to cisplatin, compared to CD117 cells. Immunohistochemical analyses with
surgical specimens of endometrial cancers showed that high CD117 expression was tightly linked to
advanced FIGO stages, myometrial invasion and histological grade, and was signiﬁcantly associated with
poor overall survival and relapse-free survival (Kaplan–Meier analysis; p < 0.001, log-rank test). The
Cox-regression hazard model identiﬁed high CD117 expression to be an independent prognostic factor
for survival (p < 0.05). In vitro assay conﬁrmed that stem cell factor (SCF), a ligand of CD117, was pro-
duced speciﬁcally in CD117+ cells of endometrial cancer, and the colony-forming activity were abrogated
by adding anti-SCF antibody, indicating an SCF-dependent growth property. Imatinib was conﬁrmed to
selectively target CD117+ cells in vitro, and synergistically enhanced the anti-tumor effect of low dose cis-
platin in vivo, which showed only modest effects when used as a single use. These ﬁndings suggest that
CD117 can be a marker of aggressive behavior of cells as well as an independent prognostic marker in
endometrial cancer. Targeting of the SCF/CD117 axis by imatinib sensitized endometrial cancer cells to
cisplatin, proposing a novel therapeutic strategy for this tumor type.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Endometrial cancer is the third most common gynecologic
cancer in Japan, and its morbidity and mortality have dramatically
increased in the past 30 years {Matsuda, 2012, Cancer Incidence
and Incidence Rates in Japan in 2006: Based on Data from 15 Pop-
ulation-based Cancer Registries in the Monitoring of Cancer Inci-
dence in Japan (MCIJ) Project}. Although the majority of patients
with early stage endometrial cancer are cured through surgery,
patients with advanced stage cancer or recurrent lesions are not
well-controlled, even with radiation and chemotherapy treatment,
for which new molecular target therapies are urgently needed.
The present study aimed to identify molecular targets for endo-
metrial cancer. The emphasis of the study was on CD117 (c-kit),
which is a cell-surface receptor tyrosine kinase type III that triggers
cell survival, proliferation, and differentiation, or other cellular
functions when stimulated by stem cell factor (SCF) [3,16,21,25].The reason for focusing on this molecule was that the speciﬁc
inhibitor has been established and available, and its effects have
been analyzed in other tumor types. CD117 has been known as a
proto-oncogene, and its gene mutation and overexpression have
been observed in gastrointestinal stromal tumors (GIST) [12], sem-
inoma [17] and leukemia [11]. Molecular target therapy using
imatinib mesylate, which blocks the tyrosine kinase activity of
CD117, is an effective treatment for GIST [6]. Recent studies have
reported interesting ﬁndings that CD117 is a potential marker of
cancer stem cells in leukemia [7], lung cancer [13] and ovarian can-
cer [27]. This background prompted us to investigate the signiﬁ-
cance of CD117 expression in endometrial cancer. We explored
the potential utility of targeting CD117 by imatinib as a novel
molecular therapy, especially when combined with cisplatin, a
key drug for conventional chemotherapy for this tumor type.
Our data showed that CD117 can be a marker of high prolifera-
tive capacity and a prognostic factor of endometrial cancer. Fur-
thermore, we report that the SCF/CD117 axis may be a potential
therapeutic target for endometrial cancer through its action of sen-
sitizing endometrial cancer cells to cisplatin.
Table 1
Correlation between CD117 expression and clmicopathological characteristics of
endometnal cancer.
Variable CD117 expression P value
Low (n = 85) High (n = 9) (Fisher’s test)
Age (y)
<60 (n = 54) 50 4 0.3144
P60 (n = 40) 35 5
FIGO stage
1, II (n = 78) 74 5 0.0336
III, IV (n = 16) 11 4
Lymph node metastasis
Negative (n = 87) 78 9 0.4822
Positive (n = 7) 7 0
Depth (myometrial invasion)
<1/2(n = 66) 63 3 0.0188
P1/2 (n = 28) 22 6
Histopathologic degree of differentiation
Grade1, 2(n = 73) 69 4 0.0243
Grade 3 (n = 21) 16 5
Menopause
Peri-/pre- (n = 68) 60 8 0.227
Post- (n = 26) 25 1
Body mass index (kg/m2)
<25 (n =58) 53 5 0.4753
P25 (n = 36) 32 4
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2.1. Cell culture
The human endometrial cancer cell lines, Ishikawa and MFE280 cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% fe-
tal bovine serum (FBS), 100 lg/mL streptomycin, and 100 IU/mL penicillin in 5% CO2
incubated at 37 C.
2.2. Flow cytometry
Cells were incubated at 4 C in phosphate-buffered saline (PBS) containing 0.5%
bovine serum albumin (BSA) and 2 mmol/L EDTA with phycoerythrin-conjugated
anti-human CD117-PE antibody (BD Biosciences, San Diego, CA, USA), and analyzed
by ﬂow cytometry (JSAN desktop cell sorter and App San software; Bay Bioscience
Co, Ltd., Kobe, Japan). CD117+ and CD117 cells were sorted using a JSAN desktop
cell sorter. Isotype-matched mouse immunoglobulin G (IgG) was used as a control.
2.3. Cell proliferation and chemosensitivity assay
The cells were seeded at a density of 3  104 or 1  105 per well in 24-well tis-
sue culture plates in DMEM with 10% FBS in 5% CO2 at 37 C. The cell number was
counted using a hemocytometer with trypan blue staining at 2, 4, 6, and 8 days after
the seeding. For the chemosensitivity assay, cells were seeded in 96-well plates at
2  103 cells/well, in DMEM medium with 10% FBS and incubated at 37 C for 24 h
before adding drug. Indicated concentrations of cisplatin (provided by Bristol Phar-
maceuticals, YK, Tokyo, Japan) were added in 0.1 mL medium, and the cells were
cultured at 37 C for 72 h. Then, the WST-1 assay (Roche Molecular Biochemicals,
Indianapolis, IN, USA) was used as described by the manufacturer.
2.4. In vitro colony formation assay
In vitro colony formation capacity was evaluated by a clonogenic assay. Diluted
single cells were plated onto 60-mm tissue culture dishes and incubated in 5% CO2
at 37 C for 8 days. Colonies larger than 250 lm in diameter were counted after
Giemsa staining.
2.5. Soft agar colony formation assay
A total of 2  104 single cells were plated in 60-mm dishes containing 0.33% soft
agar in DMEM supplemented with 10% FBS on top of 0.5% base agar in DMEM sup-
plemented with 10% FBS. Cultures were maintained in a humidiﬁed 37 C incubator.
Colonies larger than 0.25 mm were counted after incubation for 2 weeks.
2.6. Small interfering RNA (siRNA) treatment
siRNA against CD117 (sc-29225) or the negative control siRNA (sc-37007) were
purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Cells were transfected
with siRNA by the Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s instruction.
2.7. Cell cycle analysis
Cells were ﬁxed with 70% ethanol overnight at 20 C, suspended in 0.1% Triton
X-100 (in PBS) containing 25 lg/mL RNase (Sigma) for 30 min at 37 C, and then
incubated with 50 lg/mL propidium iodide (Invitrogen) to stain nuclear DNA for
30 min on ice. DNA content was analyzed using a Beckman Coulter Gallios (Beck-
man Coulter, Brea, CA, USA). Data collected from the experiments were analyzed
using Kaluza analysis software (Beckman Coulter).
2.8. Patients and clinical samples
A total of 94 patients with endometrioid-type endometrial cancer (aged
32–81 years; mean age, 58.8 years) treated at the Department of Obstetrics and
Gynecology, Kanazawa University Hospital between 1999 and 2005, were included
in this study. All patients basically underwent simple abdominal hysterectomy (or
radical abdominal hysterectomy), bilateral salpingo-oophorectomy and pelvic
lymphadenoectomy. Staging of all tumors was conducted according to the Interna-
tional Federation of Gynecology and Obstetrics (FIGO 1998) criteria. Among the 94
study patients, 63.8% of patients were diagnosed at FIGO stage I and 14.9% of pa-
tients were diagnosed at FIGO stage II, whereas 13.8% of patients were diagnosed
at FIGO stage III and 2.1% of patients were diagnosed at FIGO stage IV. Based on his-
tological examination, grade G1 was observed in 61.7%, G2 in 16.0%, and G3 in 22.3%
of patients. Adjuvant radiation therapy of the whole pelvis with an external beam
was administered at a total dose of 50.4 Gy in 31 patients with risk factors for
recurrence; i.e., deep myometrial invasion (>1/2), grade 3 tumor, cervical extension,
or extrauterine disease. Patients with positive peritoneal cytology, with lesions that
extended outside the pelvis or with lymphnode metastasis were administeredadjuvant chemotherapy in combination with Cisplatin (75 mg/m2), Doxorubicin
(50 mg/m2) and Cyclophosphamide (500 mg/m2) in 4 cycles from 1995 to 2000,
and in combination with paclitaxel (180 mg/m2) and carboplatin (AUC = 5) in 4–6
cycles since 2001. Since 2004, patients in FIGO stage III have been routinely admin-
istered adjuvant chemotherapy in combination with paclitaxel (180 mg/m2) and
carboplatin (AUC = 5) in 4–6 cycles. A total of 20 patients received platinum-based
chemotherapy.
The patients were informed and gave their consent to using tumor samples of
their hysterectomy specimens for the study. The protocol was previously approved
by the Ethics Committee of Kanazawa University.
2.9. Immunohistochemistry
Immunohistochemical analysis was performed on 4-lm-thick, formalin-ﬁxed,
parafﬁn-embedded tissue sections. After the specimens were deparafﬁnized in xy-
lene and graded alcohols, tissue sections prepared for antibody application were
pretreated with heat-induced epitope retrieval performed in a water bath with buf-
fer (pH 6.0, Target Retrieval, Dako, Carpinteria, CA, USA) for 16 h at 60 C. Afterward,
endogenous peroxidase was blocked by immersing the sections in 3% H2O2-metha-
nol for 10 min. After blocking with goat serum, the rabbit polyclonal anti-human
antibody c-kit (CD117, Dako) at 1:100 dilution was applied and incubated for
30 min at room temperature. The sections were stained for 30 min at room temper-
ature with the EnVision + HRP Kit (Dako). The reaction products were developed by
immersing the sections in a 3,30-diaminobenzidine tetrahydrochloride solution. Nu-
clei were lightly counterstained with hematoxylin. CD117 expression was assessed
semi-quantitatively by two independent investigators as follows: negative, weak
(up to 1% of cells stained), moderate (1–10%) or strong (>10%). Immunohistochem-
ically CD117-positive GIST tissue was used as positive control.
2.10. Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA (from approximately 106 cells) was isolated using the RNeasy Mini
Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. Isolated
RNA (2 lg) was reverse transcribed with the Omniscript RT Kit (Qiagen) according
to the manufacturer’s protocol. Complementary DNA was ampliﬁed using Taq poly-
merase (Nippon Gene, Tokyo, Japan). Primers and PCR conditions are listed in Ta-
ble 1. PCR products were separated and visualized on 2% agarose gel containing
ethidium bromide. The following primers were used: 50-GGTGGCAAATCTTC-
CAAAAG-30 and 50-TCTTTCACGCACTCCACAAG-30 for SCF; 50-GGCATCACGGTGACTT-
CAAT-30 and 50-GGTTTGGGGAATGCTTCATA-30 for CD117; 50-CTCAGACACCATGGGG
AAGGTGA-30 and 50-ATGATCTTGAGGCTGTTGTCATA-30 for GAPDH.
2.11. Enzyme-linked immunosorbent assay (ELISA)
The cells (2  105) were plated onto 60-mm tissue culture dishes, and cultured
in DMEM serum-free medium with PBS control, IgG control (1.0 lg/mL) (R&D Sys-
tems, Minneapolis, MN, USA) or anti-SCF (1.0 lg/mL) (R&D Systems) for 1–4 days.
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The amounts of SCF in cell culture supernatant samples were quantiﬁed by ELISA
kits (R&D Systems) according to the manufacturer’s protocol. Standard curves were
obtained by plotting known concentrations of SCF versus absorbance. Results are
presented as concentrations in pg/mL.
2.12. Xenograft models
Female 6–8-week-old Balb/c nude mouse nu/nu (Charles River, Yokohama,
Japan) were housed under speciﬁc pathogen-free conditions. Animal care was con-
ducted according to institutional guidelines. Mice were inoculated subcutaneously
into the right ﬂanks with 1  107 Ishikawa cells or 1.5  107 MFE280 cells. After tu-
mor cell inoculation, mice were randomly treated with PBS, cisplatin, imatinib, or
the combination of cisplatin with imatinib. Each group consisted of 4 mice (for
Ishikawa cells) or 6 mice (for MFE280 cells). Cisplatin (2 mg/kg for Ishikawa cells
or 0.5 mg/kg for MFE 280 cells), imatinib (30 mg/kg) and PBS were administered
intraperitoneally on Days 1, 3, and 5, Days 1, 2, 3, 4, and 5 or Days 2 and 4, respec-
tively. Tumor diameters were measured every week with calipers; tumor volume in
cubic millimeters was calculated as volume = (short diameter)2  long diameter/2.
2.13. Statistical analysis
Statistical analyses were performed using the statistical software package Stat-
View version 5.0 (Abacus Concepts, Berkeley, CA, USA). We used Student’s t-test for
2 groups or Tukey’s test for more than 2 groups for in vitro experiments. The v2 test
was used to evaluate the relationship between categorical variables in immunohis-
tochemistry assays. Survival analysis was performed using the Kaplan–Meier meth-
od, and the signiﬁcance between survival curves was determined using the log-rank
test. Multivariate survival analysis was calculated by the Cox proportional hazards
regression model in a stepwise manner for analyzing the independent prognostic
factors. Probability values of <0.05 were considered statistically signiﬁcant.
3. Results
3.1. Growth behavior and clinicopathological characteristics of CD117+
cells in endometrial cancer
We ﬁrst examined the frequency of the CD117+ subpopulation
in 2 representative endometrial cancer cell lines, Ishikawa and
MFE280 cells, by ﬂow cytometric analysis using anti-human
CD117 antibody (Supplementary Fig. 1). The CD117+ subpopula-
tion in the Ishikawa and MFE280 cell lines was approximately
2.3% and 78.7%, respectively. Since the percentage of CD117+ cells
was extremely high in MFE280 cells, we sought to conﬁrm the
expression proﬁle of CD117 during the culture. Flow-cytometric
analysis of FACS-sorted CD117+ cells revealed that the ratio of
CD117+ cells became approximately 80% on day 6 after the sorting,
returning to the initial population ratio. These ﬁndings show that
10–20% of CD117+ cells change to CD117 cells in this cell type,
maintaining high frequency of CD117+ cells (Supplementary
Fig. 2). The proliferative capacity and chemosensitivity of CD117+
cells were evaluated in vitro and in vivo using the Ishikawa and
MFE280 cell lines. Fluorescence-activated cell sorting (FACS)-
sorted CD117+ and CD117 cell populations were subjected to
the growth assay and soft agar colony formation assay. The
CD117+ populations demonstrated increased proliferative and col-
ony-forming activity compared with the CD117 populations
(Fig. 1A and B). The siRNA-based knockdown of CD117 in FACS-
sorted CD117+ cells led to cell growth retardation and inhibition
of colony-forming activity (Supplementary Fig. 3), indicating that
CD117 expression at least partially contributes to growth-compe-
tent phenotype of endometrial cancer cells. Next, sorted CD117+
and CD117 cells were treated with various concentrations of cis-
platin, and cell viability was assessed using the WST-1 assay.
CD117+ cells isolated from the two cell lines showed signiﬁcantly
reduced sensitivity to cisplatin compared with CD117 cells
(Fig. 1C), especially at lower doses. Higher doses conferred no sig-
niﬁcant difference in sensitivity, probably due to the toxic effects.
We next examined the clinicopathological signiﬁcance of
CD117 expression by immunohistochemistry using the 94 surgi-
cally removed tumors from the study patients. A total of 9 tumors(9.5%) expressed high levels of CD117, while 85 tumors (90.5%)
exhibited weak or no expression of CD117 (Fig. 2A). The correlation
between CD117 expression and clinicopathologic characteristics of
endometrial cancer was examined. CD117 expression was statisti-
cally correlated with myometrial invasion, FIGO stage and
histologic grade, but not with patient age, body mass index
(BMI), menopause or lymph node metastasis (Table 1). The 5-year
prognosis for patients with high or low/no CD117 expression was
compared; high CD117 expression was associated with poor
clinical outcome in both overall survival (OS) (44% versus 86%,
P < 0.001) and relapse-free survival (RFS) (44% versus 89%,
P < 0.0001; Fig. 2B). A Cox proportional hazards analysis of OS
and RFS was additionally performed, in which the values for
CD117 expression, myometrial invasion and FIGO stage were con-
sidered as categorical variables; high CD117 expression was found
to be an independent prognostic factor of RFS (Table 2). We further
investigated the 5-year prognosis for 20 patients who received
platinum-based adjuvant chemotherapy. As shown in Fig. 2C, pa-
tients with high CD117 expression (n = 5) had signiﬁcantly worse
OS (20% versus 73%, P < 0.05) and RFS (20% versus 73%, P < 0.05),
compared with those with low CD117 expression (n = 15).
3.2. Expression and the role of SCF in endometrial cancer cells
We next examined the expression of stem cell factor (SCF), a
CD117 ligand in CD117+ or CD117. The RT-PCR assay revealed
markedly increased expression of SCF in CD117+ Ishikawa cells
compared with CD117 cells (Fig. 3A). Secretion of SCF in the Ishik-
awa cells was also conﬁrmed by ELISA in growth media (Fig. 3B).
The addition of anti-SCF antibody into the media signiﬁcantly re-
duced the detectable levels of SCF, showing the assay speciﬁcity.
We further tested the role of SCF in stem cell activity in Ishikawa
cells. Clonogenic assay was performed with Ishikawa cells, in
which anti-SCF or control IgG were added into the media. The addi-
tion of anti-SCF signiﬁcantly inhibited the colony-forming activity
of Ishikawa cells (Fig. 3C).
3.3. Imatinib suppresses the growth of CD117+ cells in an SCF-
dependent manner and sensitizes endometrial cancer cells to cisplatin
Because the CD117+ cells had aggressive behavior, leading to
poor prognosis, we sought to target the CD117+ cells by using
imatinib, a speciﬁc inhibitor for CD117. We ﬁrst compared the sen-
sitivity of imatinib to CD117+ and CD117 cells in Ishikawa and
MFE280 cells. After treatment with various concentrations of
imatinib, cell viability was assessed using the WST-1 assay. As
shown in Fig. 4A, CD117+ cells showed signiﬁcantly greater sensi-
tivity to imatinib than CD117 cells in both cell types.
We next investigated whether the effect of imatinib is depen-
dent on SCF. Cell growth assays were performed with CD117+
and CD117 cells, in which they were treated with imatinib at
1 lM in the presence or absence of anti-SCF antibody. As shown
in Fig. 4B, imatinib inhibited the growth of CD117+ cells in the ab-
sence of anti-SCF, and the addition of anti-SCF antibody signiﬁ-
cantly abrogated this effect in CD117+ cells. CD117 cells did not
respond to imatinib, regardless of the presence of anti-SCF anti-
body. In PBS control samples, the addition of anti-SCF antibody
markedly inhibited the cell growth compared to that of control
IgG antibody (compare right and left panel in Fig. 4B), conﬁrming
the role of SCF in cell growth. These ﬁndings indicate that imatinib
suppresses the growth of CD117+ cells in an SCF-dependent
manner. We further examined whether this growth suppression
by targeting CD117 is due to cell cycle arrest or induction of
apoptosis. FACS-sorted CD117-positive cells were treated with siR-
NA-against CD117 or with Imatinib and analyzed their cell cycle
proﬁle by ﬂow-cytometry. Both knockdown of CD117 and imatinib
Fig. 1. In vitro proliferative and tumorigenic capacities of CD117+ and CD117 endometrial cancer cells. (A) FACS-sorted CD117+ or CD117 Ishikawa or MFE280 cells were
grown in normal growth media for the indicated periods, and cell number was counted using a hemocytometer with trypan blue staining. (B) A total of 2  104 FACS-sorted
CD117+ or CD117 Ishikawa or MFE280 cells were seeded on soft agar in 60-mm dishes, and colonies larger than 0.25 mm were counted after incubation for 2 weeks.
Representative colonies are shown in the photographs. (C) A total of 2  103 FACS-sorted CD117+ or CD117 Ishikawa or MFE280 cells were seeded in a 96-well plate and
exposed to various concentrations of cisplatin for 72 h in growth media. Cell viability was determined by WST-1 assay. Data are the mean ± S.D. in triplicate. P < 0.05;
P < 0.01; P < 0.001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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and G2/M fractions in Ishikawa cells (Supplementary Fig. 4A).
However, there was a signiﬁcant elevation of sub G0–G1 fraction
in the treatment with imatinib but not with siRNA-against
CD117. Therefore, the cell growth retardation by targeting CD117
appears to be due to both a decrease in cell proliferation and an
induction of apoptosis. In MFE280 cells, the knockdown of CD117
or imatinib treatment led to the increase in G0/G1 fraction and de-
crease in S and G2/M fractions. There was no change in sub G0–G1
fraction (Supplementary Fig. 4B). These ﬁnding suggest that imati-
nib may target both CD117-related and -unrelated pathways in a
cell-type dependent manner.
Our present ﬁndings suggested that CD117+ cells were likely to
be resistant to conventional chemotherapy, but relatively sensitive
to imatinib. We therefore assumed that the combination of
conventional chemotherapy with imatinib enhances antitumoractivity more than individual drug administration. To test this
hypothesis, in vitro cell growth was monitored using Ishikawa or
MFE280 cells in the absence or presence of imatinib and/or cis-
platin for appropriate periods. As shown in Fig. 5A, only mild
growth inhibition was observed with either imatinib or cisplatin
alone, while the combination treatment exhibited an apparently
potent cytotoxic effect. Soft agar colony formation assays were also
performed to determine whether the combination of imatinib and
cisplatin could affect tumorigenic growth of Ishikawa or MFE280
cells in vitro. Greater inhibition of colony formation was observed
at 4 weeks in Ishikawa or MFE280 cells when the two drugs were
combined, compared with either modality alone (Fig. 5B). We ﬁ-
nally tested the in vivo effect of combination treatment using xeno-
graft models with Ishikawa cells. The treatment groups consisted
of the following: control (PBS intraperitoneally for 5 days), imati-
nib (30 mg/kg intraperitoneally for 5 days), cisplatin (2 mg/kg for
Fig. 2. Immunohistochemical analysis of CD117 expression in endometrial cancer. (A) Representative staining of CD117 in surgical specimens of endometrial cancer are
shown. (a) A positive control for CD117 expression with a tumor specimen of a patient with GIST. Cases with no expression (b), weak expression (<1.0% of immunostaining
intensity of positive control) (c), moderate expression (1.0–10% of immunostaining intensity of positive control) (d), and strong expression (>10% of immunostaining intensity
of positive control) (e). Bars indicate 100 lm. (B) Kaplan–Meier analysis to evaluate the correlation of CD117 expression with overall and relapse-free survival of 94 patients
with endometrial cancer. (C) Kaplan–Meier analysis to evaluate the correlation of CD117 expression with overall and relapse-free survival of 20 patients who received
platinum-based adjuvant chemotherapy.
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Table 2
Cox regression hazard model with prognostic factors.
Variables Risk factor Hazard ratio (95%
conﬁdence interval)
P
FIGO stage >ll 3.98 (1.22–13.01) 0.016
Depth >1/2 4.37 (1.32–14.52) 0.01
CD117 expression High 5.90 (1.54–22.58) 0.022
X. Zhang et al. / Cancer Letters 345 (2014) 106–114 111Ishikawa cells and 0.5 mg/kg for MFE280 cells intraperitoneally for
3 days), and combination of imatinib and cisplatin. Tumor volumes
were monitored after inoculation of Ishikawa or MFE280 cells for
appropriate periods. Under the concentrations of cisplatin or imati-
nib, at which only modest growth retardation was observed in a
single use, the combination treatment showed signiﬁcantly en-
hanced growth inhibition (Fig. 5C). Notably, we did not observe
any clinical signs of toxicities in the mice treated with imatinib
(30 mg/kg) and cisplatin (2 mg/kg for Ishikawa cells and 0.5 mg/
kg for MFE280 cells). Taken together, these results suggest that
imatinib at a relatively low concentration causes no signiﬁcant ad-
verse effects, and sensitizes endometrial cancer cells to cisplatin.4. Discussion
One interesting ﬁnding in the present study is that CD117
expression is an independent prognostic factor of this tumor type.
Among the patients who received platinum-based adjuvant che-
motherapy, those with high CD117 expression had signiﬁcantly
worse OS and RFS compared to those with low CD117 expression,
supporting that CD117+ cells have cancer stem cell-like featuresFig. 3. Expression and role of SCF in endometrial cancer cells. (A) RT-PCR assay for CD1
Ishikawa cells. (B) Enzyme-linked immunosorbent assay (ELISA) measured the levels of SC
anti-SCF antibody or control IgG. Data are the mean ± S.D. in triplicate. (C) Clonogenic assa
cells. A total of 2  104 Ishikawa cells were cultured in 6-cm dishes in the presence of an
are the mean ± S.D. in triplicate. P < 0.01; P < 0.001.with chemo-resistance. Consistent with our ﬁndings, cancer pa-
tients with CD117 overexpression and/or mutations are known
to have poor prognosis in a variety of tumor types [9]. CD117 is
a surface marker for embryonic stem cells, hematopoietic stem
cells, and mesenchymal stem cells; it allows cells to remain in their
undifferentiated state, and it confers the ability for self-renewal
[1,2,15]. Accumulating evidence indicates that SCF is a mitogenic
and angiogenic factor involved in carcinogenesis [16,24]. Binding
SCF to CD117 results in the activation of its intrinsic tyrosine ki-
nase activity and promotes tumor growth. This SCF-CD117 signal-
ing loop may play a critical role in the aggressive behavior of
tumors, affecting patient survival. The present study clearly dem-
onstrated the superior efﬁcacy of imatinib on CD117+ cells. Since
SCF is up-regulated in CD117+ cells, and the blockade of SCF activ-
ity by neutralizing antibody abrogated the efﬁcacy of imatinib,
imatinib is thought to inhibit growth of CD117+ cells in an SCF-
dependent manner. In fact, imatinib showed no effect on CD117
cells with low or faint SCF expression. This growth suppression
by targeting CD117 was found to be mainly due to cell cycle arrest,
not apoptosis induction in MFE280 cells (Supplementary Fig. 3A).
However, since slight increase in apoptosis fraction was observed
in Ishikawa cells by the treatment with imatinib (Supplementary
Fig. 3B), imatinib may target both CD117-related and –unrelated
pathways in a cell-type speciﬁc manner. Nevertheless, it is specu-
lated that SCF plays a critical role as a mitogenic factor in the
growth of CD117+ cells, and the SCF/CD117 axis is a mechanical
point on which imatinib exerts antitumor activities.
Considering the uses and potential effects of molecular target
therapy, the percentage of CD117+ cells in tumor burden should
be concerning. Immunohistochemistry showed that the percentage
of CD117+ cells varied among patients, and that patients with17 and the CD117 ligand, stem cell factor (SCF) in FACS-sorted CD117+ or CD117
F secretion in Ishikawa cells cultured in growth media in the absence or presence of
y to examine the effects of anti-SCF antibody on colony-forming activity of Ishikawa
ti-SCF antibody or control IgG for 6 days, and the colony number was counted. Data
Fig. 4. Effects of imatinib on endometrial cancer cells. (A) A total of 2  103 FACS-sorted CD117+ or CD117 cells were cultured in 96-well plates and treated with imatinib at
indicated concentrations for 72 h, and the cell viability was examined by WST-1 assay. (B, C). A total of 2  103 FACS-sorted CD117+ (B) or CD117 (C) cells were cultured in
96-well plates and treated with imatinib at 8 lM in the presence of anti-SCF antibody or control IgG for 72 h, and the WST-1 assay was performed. Data are the mean ± S.D. in
triplicate. P < 0.05; P < 0.01.
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tumors are therefore CD117 cells, which conventional chemo-
therapies should mainly target. Several clinical trials have been
attempted with a single use of imatinib, both in recurrent gyneco-
logic tumors and as a maintenance agent in patients following a
complete clinical remission; however, all of them have demon-
strated no or little efﬁcacy [10,19]. These background results
prompted us to attempt combination treatment with imatinib
and cisplatin, based on the speculation that CD117-positive cancer
stem-like cells are the source of more differentiated daughter cells
that occupy the tumor, while CD117-negative cells fail to generate
such cells. Targeting CD117+ cells will therefore lead to depletionof tumor-forming daughter cells while most of CD117 cells that
initially occupy tumor are sensitive to conventional chemotherapy,
thereby exhibiting enhanced growth inhibitory effect in combina-
tion.In vitro evaluation by assessing growth curve and colony for-
mation revealed that imatinib at 4 lM or cisplatin at 2 lM had a
modest effect in a single dose. However, combining them produced
a signiﬁcantly enhanced effect. It was of note that this combined
effect was exaggerated in vivo. While a single dose of imatinib at
30 mg/kg or cisplatin at 2 mg/kg in mice showed minimal effects
on tumor growth, combined administration achieved far more sig-
niﬁcant growth inhibition. Notably, growth inhibition appeared in
a week after the ﬁnal treatment with the agents, much earlier than
Fig. 5. Imatinib sensitizes endometrial cancer cells to cisplatin. (A) A total of 3 x 103 Ishikawa or 2  104 MFE280 cells were seeded in 24-well plates and treated with
imatinib with or without cisplatin at the indicated concentrations for various days. The mean numbers of cells per well were counted and shown. Data are the mean ± S.D. in
triplicate. (B) A total of 6  104 Ishikawa or 5  104 MFE280 cells were seeded in 6-cm dishes and treated with imatinib and/or cisplatin at the indicated concentrations for
14 days. The colony numbers per well were counted and shown. Data are the mean ± S.D. in triplicate. (C) Nude mice were inoculated subcutaneously into the right ﬂanks
with 1  107 Ishikawa cells or 1.5  107 MFE280 cells. After tumor cell inoculation, mice were randomly treated with PBS, cisplatin, imatinib, or the combination of cisplatin
with imatinib. Each group consisted of 4 mice (for Ishikawa cells) or 6 mice (for MFE280 cells). Cisplatin (2 mg/kg for Ishikawa cells or 0.5 mg/kg for MFE 280 cells), imatinib
(30 mg/kg) and PBS were administered intraperitoneally on Days 1, 3, and 5, Days 1, 2, 3, 4, and 5 or Days 2 and 4, respectively. Tumor diameters were measured every week
and are shown as mean ± SE. P < 0.05; P < 0.01; P < 0.001.
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vealed a prominent shrink in tumor volume (1/4–1/5) compared
with controls or samples with single use of each agent. It is thus
possible that the combination had a synergistic effect, rather than
an additive effect. The fact that no signiﬁcant effect on tumor
growth was observed by a single use of imatinib alone might show
a limitation of imatinib in targeting CD117+ cells alone, leaving
CD117 cells untargeted.
What are the mechanisms of the enhanced effect by using a
combination in vivo? Cisplatin treatment is known to induce a vari-
ety of survival signalings, including hypoxia-inducible factor (HIF)-
1 or Akt signalings [8,18,20]. HIF-1 induction is reported to induce
SCF; SCF can up-regulate HIF-1 transcription, thereby forming a
positive activation loop, which must promote angiogenesis
in vivo [5,14,26]. Such a microenvironment will disturb the effect
of cisplatin or induce resistance in vivo. The action of imatinib on
the SCF/CD117 axis may target this positive loop, inhibiting tumor
angiogenesis. In fact, the inhibitory effect of imatinib on tumor
angiogenesis has been reported in other tumor types [14,23]. Addi-
tionally, the inhibitory effect of imatinib on CD117+ cells is associ-
ated with the down-regulation of pro-survival signaling, such as
Akt signalings [4,22], the representative signalings related to cis-
platin resistance. These effects will contribute overall to enhancing
the effects of cisplatin.
In summary, we identiﬁed CD117 as a marker of aggressive
behavior of cells in endometrial cancer and as an independent
prognostic factor for endometrial cancer. Imatinib inhibited the
growth of CD117+ cells in an SCF-dependent manner. Cisplatin
treatment combined with imatinib conferred enhanced anti-tumor
effects compared with a single use of each agent, probably inhibit-
ing both CD117+ and CD117 populations. Profound mechanistic
analysis will be needed to uncover the molecular mechanisms of
this enhanced anti-tumor effect for future clinical use. Further-
more, analysis of the combined effects of imatinib with other
agents, such as taxanes, will provide greater opportunity for clini-
cal application of imatinib in endometrial cancer.
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